The Nationwide Austrian Aspergillus Registry: A prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients

International Journal of Antimicrobial Agents

Volumn 36, Issue 6, 2010, Pages 531-536

  Perkhofer, S ^a   Lass Florl C ^a   Hell, M ^b   Russ, G ^c   Krause, R ^d   Honigl M ^d   Geltner, C ^e   uberger, J ^a   Gastl, G ^a   Mitterbauer, M ^f   Willinger, B ^f   Knobl P ^f   Resch, G ^g   Waldner, R ^h   Makrai, A ^h   Hartmann, G ⁱ   Girschikofsky, M ^j   Greil, R ^c  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF SALZBURG   (Austria)

^c Private Medical University Salzburg   (Austria)

^d MEDICAL UNIVERSITY OF GRAZ   (Austria)

^e National Pulmonary Hospital Natters   (Austria)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g Klinikum Wels   (Austria)

^h HANUSCH HOSPITAL   (Austria)

ⁱ Universitäres Lehrkrankenhaus Feldkirch ^*  (Austria)

^j ELISABETHINEN HOSPITAL   (Austria)

more..

Author keywords

Antifungal treatment; Aspergillosis; Austrian National Registry; Leukaemia; Transplantation; Zygomycosis

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; ASPERGILLUS; AUSTRIA; CHEMOPROPHYLAXIS; CLINICAL TRIAL; FEMALE; GRAFT RECIPIENT; HIGH RISK PATIENT; HUMAN; IMMUNE DEFICIENCY; IMMUNOCOMPROMISED PATIENT; INCIDENCE; INFECTION RISK; INVASIVE ASPERGILLOSIS; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; MYCOSIS; OBSERVATIONAL STUDY; OUTCOMES RESEARCH; PREVALENCE; PRIORITY JOURNAL; REGISTER; SURVIVAL RATE; ZYGOMYCETES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; ASPERGILLOSIS; AUSTRIA; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; INCIDENCE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78249285274     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.08.010     Document Type: Article

References (39)

1. Neofytos D., Horn D., Anaissie E., Steinbach W., Olyaei A., Fishman J., et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009, 48:265-273.
2. Singh N., Paterson D. Aspergillus infections in transplant recipients. Clin Microbiol Rev 2005, 18:44-69.
3. Singh N. Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis 2001, 33:1692-1696.
4. Segal B. Aspergillosis. N Engl J Med 2009, 360:1870-1884.
5. Malani A., Kauffman C. Changing epidemiology of rare mould infections: implications for therapy. Drugs 2007, 67:1803-1812.
6. Marr K.A., Crippa F., Leisenring W., Hoyle M., Boeckh M., Balajee S.A., et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004, 103:1527-1533.
7. Marr A.K., Carter R., Crippa F., Wald A., Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002, 34:909-917.
8. Upton A., Marr A.K. Emergence of opportunistic mould infections in the hematopoietic stem cell transplant patient. Curr Infect Dis Rep 2006, 8:434-441.
9. Patterson T. Advances and challenges in management of invasive mycoses. Lancet 2005, 17:1013-1025.
10. Lortholary O., Charlemagne A., Bastides F., Chevalier P., Datry A., Gonzalves M.F., et al. A multicentre pharmacoepidemiological study of therapeutic practices in invasive fungal infections in France during 1998-1999. J Antimicrob Chemother 2004, 54:456-464.
11. Pappas P. Amphotericin B lipid complex in the treatment of invasive fungal infections: results of the Collaborative Exchange of Antifungal Research (CLEAR), an industry supported patient registry: introduction. Clin Infect Dis 2005, 40(Suppl. 6):S379-S383.
12. De Pauw B., Walsh T.J., Donnelly J.P., Stevens D.A., Edwards J.E., Calandra T., et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008, 46:1813-1821.
13. Walsh T.J., Anaissie E.J., Denning D.W., Herbrecht R., Kontoyiannis D.P., Marr K.A., et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2009, 46:327-360.
14. Maertens J., Frere P., Lass-Flörl C., Heinz W., Cornely O.A. Primary antifungal prophylaxis in leukaemia patients. Eur J Cancer 2007, (Suppl. 5):43-48.
15. Post M., Lass-Flörl C., Gastl G., Nachbaur D. Invasive fungal infections in allogeneic and autologous stem cell transplant recipients: a single-center study of 166 transplanted patients. Transpl Infect Dis 2007, 9:189-195.
16. Almyroudis N.G., Sutton D.A., Linden P., Rinaldi M.G., Fung J., Kusne S. Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature. Am J Transplant 2006, 6:2365-2375.
17. Kontoyiannis D.P., Lionakis M.S., Lewis R.E., Chamilos G., Healy M., Perego C., et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005, 191:1350-1360.
18. Chamilos G., Luna M., Lewis R.E., Bodey G.P., Chemaly R., Tarrand J.J., et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 2006, 91:986-989.
19. Pagano L., Caira M., Candoni A., Offidani M., Fianchi L., Martino B., et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006, 91:1068-1075.
20. Lass-Flörl C., Resch G., Nachbaur D., Mayr A., Gastl G., Auberger J., et al. The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients. Clin Infect Dis 2007, 45:e101-e104.
21. Lass-Flörl C., Griff K., Mayr A., Petzer A., Gastl G., Bonatti H., et al. Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience. Br J Haematol 2005, 131:201-207.
22. Aisner J., Wiernik P.H., Schimpff S.C. Treatment of invasive aspergillosis: relation of early diagnosis and treatment to response. Ann Intern Med 1977, 86:539-543.
23. Bodey G., Bueltmann B., Duguid W., Gibbs D., Hanak H., Hotchi M., et al. Fungal infections in cancer patients: an international autopsy study. Eur J Clin Microbiol Infect Dis 1992, 11:99-109.
24. Herbrecht R., Denning D.W., Patterson T.F., Bennett J.E., Greene R.E., Oestmann J.W., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002, 347:408-415.
25. Anaissie E. Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Clin Infect Dis 1992, 14(Suppl. 1):S43-S53.
26. Denning D.W. Epidemiology and pathogenesis of systemic fungal infections in the immunocompromised host. J Antimicrob Chemother 1991, 28:1-16.
27. Pfaller M.A. Epidemiological typing methods for mycosis. Clin Infect Dis 1992, 14:4-10.
28. Horn D.L., Fishman J.A., Steinbach W.J., Anaissie E.J., Marr K.A., Olyaei A.J., et al. Presentation of the PATH Alliance registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections. Diagn Microbiol Infect Dis 2007, 59:407-414.
29. Auberger J., Lass-Flörl C., Ulmer H., Nogler-Semenitz E., Clausen J., Gunsilius E., et al. Significant alterations in the epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies. Int J Hematol 2008, 88:508-515.
30. Martino R., Viscoli C. Empirical antifungal therapy in patients with neutropenia and persistent or recurrent fever of unknown origin. Br J Haematol 2006, 132:138-154.
31. Müller C., Arndt M., Queckenberg C., Cornely O., Theisohn M. HPLC analysis of the antifungal agent posaconazole in patients with haematological diseases. Mycoses 2006, 49:17-22.
32. Lass-Flörl C. The changing face of epidemiology of invasive fungal diseases in Europe. Mycoses 2009, 52:197-205.
33. Groll A.H., Shah P.M., Menzel C., Schneider M., Just-Nuebling G., Huebner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996, 33:23-32.
34. Trifilio S.M., Bennett C.L., Yarnold P.R., McKoy J.M., Parada J., Mehta J., et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 2007, 39:425-429.
35. Lafaurie M., Lapalu J., Raffoux E., Breton B., Lacroix C., Socié G., et al. High rate of breakthrough invasive aspergillosis among patients receiving caspofungin for persistent fever and neutropenia. Clin Microbiol Infect 2010, 16:1191-1196.
36. Walsh T.J., Pappas P., Winston D.J., Lazarus H.M., Petersen F., Raffalli J., et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002, 346:225-234.
37. Vehreschild J.J., Böhme A., Buchheidt D., Arenz D., Harnischmacher U., Heussel C.P., et al. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). J Infect 2007, 55:445-449.
38. Cornely O.A., Maertens J., Winston D.J., Perfect J., Ullmann A.J., Walsh T.J., et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007, 356:348-359.
39. Ullmann A.J., Lipton J.H., Vesole D.H., Chandrasekar P., Langston A., Tarantolo S.R., et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007, 25:335-347.